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Abstract
Background: Regarding the growing prevalence of non-alcoholic fatty liver disease, concentrating on various strategies for its
prevention and management seems necessary.
Objectives: This study aimed to assess the effects of synbiotic administration on body composition and lipid profile in patients with
NAFLD.
Methods: Eighty patients with NAFLD participated in this randomized, double-blind, placebo-controlled clinical trial (from March
to July 2014) in Iran. Based on AST and ALT as main variables of the study, 34 patients were required in each group (power 80% and
α = 5%). Considering a 20% sample loss, 80 patients were enrolled. Synbiotic supplement in form of a 500 mg capsule (containing
7 species of probiotic bacteria and Fructooligosaccharides) was administrated to patients in the intervention group and those in
the placebo group received 1 placebo capsule daily for 8 weeks. At the baseline and the end of the study, body composition and lipid
profile were evaluated.
Results: A significant reduction was observed in weight (P = 0.001), body fat (P = 0.02), and total cholesterol (P = 0.04) within the
synbiotic group. On the other hand, WC (P = 0.02), total cholesterol, and LDL-c (P = 0.04 and P = 0.001, respectively) were significantly
increased in the placebo group. TG, HDL-c, and FBG levels remained statistically unchanged in both groups. Significance between-
group differences were seen in total cholesterol (P = 0.01), LDL (P = 0.01), weight, WC, and body fat after adjustment for energy intake
(P = 0.05).
Conclusions: Synbiotic supplementation may improve lipid profile and body composition in patients with NAFLD and might be
useful in prevention of the disease progression.
Keywords: Nonalcoholic Fatty Liver Disease, Symbiotic, Body Composition, Total Cholesterol, LDL- Cholesterol, HDL- Cholesterol,
Lipid Profile
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is a health
problem in the world and is the most common chronic
liver disease that has spread parallel to the epidemic obe-
sity (1, 2). The prevalence of NAFLD in the general popu-
lation has been reported between 2.8 to 30% in different
countries (3, 4), with Iran being an estimated 7% for chil-
dren and 35% for adults (5, 6). Changes in intestinal bacte-
rial flora due to stress or poor nutritional habits are impor-
tant in the pathogenesis or progression of NAFLD (7).
On the other hand, most of studies on the relationship
between microbial flora and obesity observed significant
changes in composition and metabolic function of gut mi-
crobiome in obese individuals (8, 9). It seems that obesity is
associated with certain intestinal microbiome, which have
the ability to have more energy extraction from diet and
cause more fatty acids uptake in the liver and peripheral
tissues (10).
Several studies have supported the hypothesis that
small intestinal bacterial over growth and qualitative
changes in microbiom may contribute to obesity and
NAFLD progression. Based on beneficial effects of probi-
otics and prebiotics on the human intestinal microbial
ecosystem, they have been suggested as a complementary
therapeutic approach in NAFLD (11-13).
Most investigations regarding NAFLD treatment have
been conducted on overweight and obese patients, and to
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our knowledge, there is no study that has investigated the
effect of symbiotic alone on body composition and lipid
profile in lean and normal weight NAFLD patients. Accord-
ingly, with respect to the high prevalence of NAFLD in our
country, more researches on treatment of these patients
seem necessary. Therefore, in the present clinical trial we
evaluated the effect of short-term synbiotic supplementa-
tion, as a simple, low cost, and without side effect treat-
ment component on lipid profile and body composition in
NAFLD patients while addressing some of the mechanisms
of action by which synbiotic may function.
2. Methods
The protocol of this randomized, double blind,
placebo-controlled clinical trial was approved by the Re-
search Ethics Committee of Isfahan University of Medical
Sciences and registered in the Iranian registry of clinical
trial (IRCT2013122811763N15) (www.irct.ir).
NAFLD volunteers (by ultrasound and high levels of as-
partate aminotransferase (AST) and alanine aminotrans-
ferase (ALT)) were referred to the Isfahan endocrine and
metabolism research center and enrolled into this study
(from March to July 2014). Based on AST and ALT as main
variables of the study, 34 patients were required in each
group (power 80% and α = 5%). Considering a 20% sam-
ple loss, 80 patients were enrolled. Subjects were selected
by systematic random sampling. We first randomly picked
the first subject from a list of 330 patients referred to the
endocrine and metabolism research center. Then, we se-
lected each fourth subject from the list. The inclusion
criteria included individuals between the ages of 18 - 60
years, no other liver disease, no inflammatory bowel dis-
ease, no self-reported specific disease and malignancies, no
pregnancy and lactation, no vitamin-mineral, antioxidant,
and omega-3 supplementation. Study volunteers were ex-
cluded for failure to follow trial guidelines (< 90% com-
pliance, subject’s compliance was evaluated by counting
the remaining capsules at the end of the fourth and eight
weeks).
Random assignment was done by block randomiza-
tion. After block size has been determined (4 subjects),
all possible balanced combinations of assignment within
the block was calculated. Blocks were then randomly cho-
sen to determine the patients’ assignment into the groups.
Participants were randomly allocated to 2 numerically
equal groups from a double-blind, 80-person list, using a
table of random digits and given either a synbiotic in form
of a 500 mg capsule (Familact, produced by Zisttakhmir
company) containing 7 species of probiotic bacteria (Lacto-
bacillus casei, Lactobacillus acidopholus, Lactobacillus rham-
nosus, Lactobacillus bulgaricus, Bifidobacteriumbreve, Bifi-
dobacteriumlongum, Streptococcus thermophiles) and fruc-
tooligosaccharides or a placebo capsule (containing 120
mg starch, similar in shape and appearance).
The boxes containing the symbiotic and placebo cap-
sules were coded (A and B) by an individual who was
not aware of research objectives and investigators were
blinded for the entire duration of the study. Study partici-
pants, as well as the placebo group, ingested those capsules
once daily after dinner for 8 weeks. Six participants were
excluded during the study (because of < 90% compliance,
personal reasons and antibiotic therapy), which left 38 vol-
unteers in the synbiotic group and 36 in the placebo group
(Figure 1).
At the beginning of the study, enough information re-
garding the study and its process was given to all partici-
pants and written informed consent was obtained. All tests
and evaluations were free of charge. General information
was collected using an interview. Body weight was mea-
sured to the nearest 0.1 kg with minimal clothing by means
of a calibrated digital seca balance (Seca, Hamburg, Ger-
many). Height was measured to the nearest 0.5 cm with-
out shoes by means of a calibrated seca stadiometer (Seca,
Hamburg, Germany). Body mass index was calculated (BMI
= weight in kg/height2 in m). Waist and hip circumfer-
ence were measured on a horizontal plane at the level of
the iliac crest by an Ergonomic Circumference Measuring
Tape. Body fat, lean body mass (LBM), and total body water
(TBW) were measured using a body composition analyzer
(Jawon Medical Company, Korea) while subjects were wear-
ing light clothes and had bare feet and hands after 5 min-
utes resting. All measurements were performed by 1 per-
son.
After a 12-hour overnight fast, venous blood samples
were collected. After centrifugation, the serum sam-
ples were frozen and stored at -70°C. Fasting blood glu-
cose (FBG) was measured by means of glucose hexokinase
method; serum triglyceride (TG), high density lipoprotein
(HDL), and total cholestrole were measured with enzy-
matic method (using commercial kits, Pars Azmoon Com-
pany, Tehran, Iran), and low density lipoprotein (LDL) was
calculated using Friedwald formula.
Physical activity levels and dietary intake (3-day food
record in gram before, and the same after intervention)
were recorded at the baseline and the end of the study.
Metabolic equivalent of task (MET) was used as a means
of expressing intensity of recorded activities (14). Dietary
data were analyzed using the Nutritionist IV software ad-
justed for Iranian foods (Version 4.1, First Databank Divi-
sion, The Hearst Corporation, San Bruno, CA, USA).
Software package statistical analysis (SPSS, version 20;
SPSS Inc, Chicago, IL, USA) was used for all statistical anal-
yses. Descriptive statistics are presented as mean ± stan-
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Figure 1. Follow Chart of Participants Throughout the Study
dard deviation (SD). The normality of data was checked by
the Shapiro-Wilk test. Paired t-test (in case of normal distri-
bution) or nonparametric statistical test, Wilcoxon signed
rank test (in case of non-normal distribution), was used
for comparing data within groups. Independent t-test (in
case of normal distribution) or nonparametric statistical
test, Mann–Whitney (in case of non-normal distribution),
was used for comparing data between two groups. Analysis
of covariance (ANCOVA) was used for evaluating between
group differences based on quantitative data; adjustment
was made for differences in baseline covariates. Within
and between groups, differences based on qualitative vari-
ables were assessed using McNemar and Chi-square tests,
respectively. All tests were two-sided and P values < 0.05
were considered statistically significant.
3. Results
Baseline characteristics were similar in the synbiotic
and placebo groups (Table 1). No significant differences
were found between the 2 groups at the baseline.
FBG and lipid profile were reported in Figure 2. To-
tal cholesterol was significantly decreased in the synbiotic
group after the intervention (P = 0.04), total cholesterol
and LDL (P = 0.04 and P = 0.001, respectively) were signif-
icantly increased in the placebo group. TG, HDL, and FBG
showed no significant change in either group. ANCOVA
shows significant differences in total cholesterol (P = 0.01)
and LDL (P = 0.01) between groups but detected no differ-
ences in FBG, TG, and HDL between groups after adjust-
ment for energy intake.
Table 2 shows a comparison of body composition
changes between groups. Weight and body fat decreased
in the synbiotic group significantly (P = 0.001 and P = 0.02,
respectively) and waste circumference (WC) increased in
the placebo group significantly (P = 0.02). Other variables,
including body mass index (BMI), waist/hip ratio (WHR),
lean body mass (LBM), slim lean mass (SLM), protein (Pr),
mineral (Min), and total body water (TBW) remain un-
changed in both groups. Comparison of body composition
variables between groups through multivariable analysis
of covariance with adjustment for energy intake and base-
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Table 1. Baseline Characteristics of the Study Participantsa
General
Characteristics
Symbiotic (n = 38) Placebo (n = 36) P Value
Age, yb 46.57± 1.7 47.78± 1.7 0.62
Womenc 33 (82.5) 22 (64.7) 0.11
Men c 7 (17.5) 12 (35.3) 0.11
Weight, kgb 75.21± 2.14 73.90± 2.20 0.67
Height, cmb 159.25± 1.51 162.66± 1.66 0.13
BMI, kg/m2 b 29.58± 0.76 28.18± 0.68 0.18
WC, cmb 90.82± 1.74 88.91± 1.57 0.42
WHRb 0.910± 0.01 0.895± 0.01 0.47
Body fatb 26.56± 1.08 24.54± 1.25 0.22
LBMd 48.93± 1.37 50.15± 1.66 0.88
TBWc 34.75± 1.18 36.25± 1.24 0.73
Physical activity,
mc
33.42± 0.47 34.75± 1.05 0.49
Energy intake,
kcal/db
2116.62±95.48 2200.28± 109.33 0.56
Carbohydrate
intake g/dd
306.99± 17.93 307.00± 14.36 0.74
Protein intake, g/db 67.01± 3.84 72.15± 4.05 0.36
Fat intake, g/db 72.28± 5.08 78.87± 6.72 0.43
Vitamin C intake,
mg/dayd
114.79± 20.83 80.78± 10.86 0.40
Vitamin E intake,
mg/dd
37.00± 4.03 44.89± 5.36 0.23
FBGd 97.48± 1.49 101.46± 2.40 0.30
TGd 162.61± 11.86 174.71± 20.49 0.96
Total Chold 203.05± 8.04 187.41± 6.64 0.35
LDLd 121.55± 6.81 104.73± 6.12 0.22
HDLd 45.36± 1.94 45.25± 1.80 0.80
Abbreviations: BMI, body mass index; FBG, fasting blood glucose; HDL, high
density lipoprotein; LBM, lean body mass; LDL, low density lipoprotein; TBW,
total body water; TG, triglyceride; total chol, total cholesterol; WC, waist cir-
cumference; WHR, waste/hip ratio.
aValues are expressed as mean± SE or No. (%).
bIndependent T test.
cChi square.
dMann-whitney.
line values showed no significant difference.
4. Discussion
Increasing prevalence of NAFLD in general population
of different countries call for natural and safe strategies
for management of this disease. Already, there is no regis-
tered drug for the treatment of NAFLD (15, 16). NAFLD treat-
ment specially focuses on life-style modifications (17). Re-
sults emerging from the present study demonstrate that
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Figure 2. Lipid Profile and FBG of Participants Before and After Intervention 1
synbiotic supplementation in NAFLD patients significantly
improved body composition and lipid profile.
Our results are consistent with results from differ-
ent studies. Lee et al. in an experimental study found
that Lactobacillus rhamnosus produce conjugated linoleic
acid and indicate anti-obesity effects in diet-induced obese
mice (18). Sato et al. evaluated the effects of milk fer-
mented by Lactobacillus gasseri on adipocyte size in rats
and achieved similar results (19). Ley RE et al. evaluated
16SrRNA gene sequences from the gutmicrobiota of genet-
ically obese ob/ob mice. They reported specific changes in
gut microbiota composition, which could result in the in-
creased short chain fatty acids (SCFAs) production and en-
ergy harvest (20). Festi et al. in a review, confirmed the
pathogenic role exerted by gut microbiota on the develop-
ment of metabolic disorders. They concluded that prebi-
otics or probiotics administration could improve gut bar-
rier integrity, thus, ameliorating metabolic balance and
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Table 2. Body Composition of Participants Before and After the Intervention
Symbiotic Group (n = 38) Placebo Group (n = 36) P Valuea P Valueb
Mean± SE P Valuec Mean± SE P Valuec
Weight
Before 74.53± 2.08
0.001
73.66± 2.31
0.16 0.001 0.05After 73.76± 2.07 74.99± 2.39
Dif -0.76± 0.22 1.33± 0.93
BMI
Before 29.16± 0.70
0.46
28.00± 0.70
0.27 0.06 0.33After 29.08± 0.70 28.51± 0.85
Dif -0.07± 0.10 0.51± 0.46
WC
Before 90.07± 1.75
0.14
88.84± 1.67
0.02 0.001 0.05After 89.25± 1.58 90.32±1.76
Dif -0.82± 0.54 1.48± 0.60
WHR
Before 0.90± 0.01
0.44
0.89± 0.01
0.59 0.85 0.34After 0.89± 0.01 0.88± 0.03
Dif -0.01± 0.00 3.55± 3.57
Body fat
Before 26.56± 1.08
0.02
24.54± 1.25
0.26 0.001 0.05After 25.19± 1.15 25.43± 1.43
Dif -0.91± 0.39 -0.01± 0.68
LBM
Before 26.10± 1.06
0.24d
24.24± 1.31
0.45d 0.97 0.59After 25.19± 1.15 25.01± 1.39
Dif -0.91± 0.39 0.77± 0.68
TBW
Before 34.47± 1.22
0.60d
36.33± 1.31
0.42d 0.69 0.17After 34.87± 1.04 35.98± 1.22
Dif 0.40± 0.48 -0.35± 0.37
aMann-whitney (comparison of different between groups).
bANCOVA (adjusted for energy intake).
cPaired T test.
dWilcoxon.
promoting weight loss (21).
Probiotics can influence host metabolism in various
ways. There is a specific microbiota in obese subject that
extract energy from the diet more effectively. Microbial
products, mainly SCFAs, influence on host’s metabolism,
intestinal transit time, energy absorption and appetite.
Moreover, the complex interactions between gut micro-
biota and host’s immune system may contribute to devel-
opment of obesity (10, 21).
Our study demonstrated a reduction in total and LDL
cholesterol that was statistically significant, whereas, in
placebo group total and LDL cholesterol increased signif-
icantly. Change in cholesterol level was not unexpected as
over several years, more and more experimental and clini-
cal trials indicated that probiotics could lead to a decrease
in serum cholesterol (22-26). Findings of a recent meta-
analysis indicated that probiotics had a significantly good
effect on normalizing total cholesterol, as we observed
(27). Ghasemi findings also indicated that the addition
of synbiotic to the diet decreased serum cholesterol and
LDL cholesterol concentrations in broilers (28). In contrast
with our results, Wong VW et al. did not find any significant
effect for Lepicol probiotic and prebiotic formula on body
mass index, waist circumference, glucose, and lipid levels
(29).
Our results showed no significant change in TG and
HDL cholesterol. In 2013, Bhathena et al. observed that the
cholesterol fraction had more reduction compared to hep-
atic neutral lipids, whereas the proportion of TG remained
unchanged. Free cholesterol accumulation in the mito-
chondria, but not TG, is known to sensitize hepatocytes to
cytokine-induced apoptosis and disease progression. Pro-
biotic is thought to reduce cholesterol augmentation in
the mitochondria and restore antioxidant levels, offering
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some protection from liver damage (7). Moreover, fermen-
tation products of lactic acid bacteria inhibit cholesterol-
synthesizing enzymes and thus reduce cholesterol produc-
tion. The bacteria may facilitate elimination of cholesterol
in feces and may inhibit its reabsorption into the body; in
addition, these bacteria may interfere with the recycling of
bile salt (a metabolic product of cholesterol) (22, 24). We
observed no effect on HDL level, may be HDL requires long-
term intervention to change or there are unknown mech-
anisms in this regard (27).
Our synbiotic capsules were containing Fruc-
tooligosaccharides, which are now becoming increasingly
popular due to their prebiotic effects. They can enhance
the growth of Bifidobacteria or Lactobacilli and may help
control or reduce the growth of harmful bacteria (30).
Moreover, they contribute to reduce body weight and
body fat by modulating food intake and appetite, by pro-
moting the production of glucagon-like peptide-1 (GLP-1),
peptide YY, and the decrease of ghrelin, as well as, at the
same time, by decreasing fatty acid storage (21). Few stud-
ies have used a combination of probiotics and prebiotics
in the form of supplements to evaluate their exclusive
effects on patients with NAFLD. To our knowledge, the
present study is the first double blind placebo controlled
clinical trial that evaluated the effect of symbiotic as a low
cost therapeutic component without side effects on body
composition and lipid profile in lean and normal weight
NAFLD patients.
Several limitations must be considered in the interpre-
tation of our findings, including limited duration of clini-
cal trial and sample size. Ultrasound was used to approve
NAFLD in participants. It is well known that liver histology
is the gold standard for NAFLD/NASH diagnosis. Although
an ultrasound is reasonably accurate, it cannot identify
fatty infiltration of the liver below a threshold of 30% (27).
Other possible probiotic sources, especially dairies were
not controlled in this study since they are an important
part of a usual diet in our population. Furthermore, due to
budget limitation we were not able to evaluate other fac-
tors and focal microbiota change. More clinical trials, with
longer intervention periods and higher dosage of symbi-
otic, may show better results.
In conclusion synbiotic supplementation could im-
prove body composition and lipid profile in NAFLD pa-
tients and might be useful in management of NAFLD or be
protective against progression of the disease.
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